CN106519007B - 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 - Google Patents
一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 Download PDFInfo
- Publication number
- CN106519007B CN106519007B CN201611138456.XA CN201611138456A CN106519007B CN 106519007 B CN106519007 B CN 106519007B CN 201611138456 A CN201611138456 A CN 201611138456A CN 106519007 B CN106519007 B CN 106519007B
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- wsgc
- peptide
- medicament
- chain polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 66
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 41
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 41
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000009950 gastric cancer growth Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000002953 phosphate buffered saline Substances 0.000 abstract description 2
- 239000002504 physiological saline solution Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- INKFLNZBTSNFON-CIUDSAMLSA-N Gln-Ala-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O INKFLNZBTSNFON-CIUDSAMLSA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- DAHLWSFUXOHMIA-FXQIFTODSA-N Glu-Ser-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O DAHLWSFUXOHMIA-FXQIFTODSA-N 0.000 description 1
- AWASVTXPTOLPPP-MBLNEYKQSA-N His-Ala-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AWASVTXPTOLPPP-MBLNEYKQSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010071034 Microsomia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- SMIDBHKWSYUBRZ-ACZMJKKPSA-N Ser-Glu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O SMIDBHKWSYUBRZ-ACZMJKKPSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- TVPQRPNBYCRRLL-IHRRRGAJSA-N Ser-Phe-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O TVPQRPNBYCRRLL-IHRRRGAJSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- NKMFRGPKTIEXSK-ULQDDVLXSA-N Tyr-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NKMFRGPKTIEXSK-ULQDDVLXSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- IZFVRRYRMQFVGX-NRPADANISA-N Val-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N IZFVRRYRMQFVGX-NRPADANISA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种单链多肽，其氨基酸序列为SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQAR，分子量为4344g/mol。本发明的单链多肽在制备用于预防和治疗胃癌的药物中的应用，其药物中的有效成分为WSGC肽。本发明的用于预防和治疗胃癌的药物形式为单链化合物，可溶解于纯水、生理盐水或PBS缓冲液中。实验证明，本发明制备的多肽药物通过抑制胃癌细胞的增殖与生长，达到治疗胃癌的作用，并可在预防和治疗胃癌中得到广泛应用。
Description
技术领域
本发明涉及生物医药领域，尤其是涉及一种单链多肽，本发明还涉及该多肽在制备用于预防和治疗胃癌的药物中的应用。
背景技术
胃癌在全球范围内发病率高，死亡率高，明确诊断时大多已到晚期，5年生存率低于25%，且目前缺乏有效的治疗手段。传统小分子药物的非特异性毒性限制了其大范围的临床应用及市场推广，而多肽类药物由于具有不蓄积中毒、相对成本低、生物活性强、副作用小、作用靶点专一等优点，日渐引起制药企业及学术界的关注，已广泛涉足抗肿瘤药物、心脑血管药物、抗病毒多肽、抗菌性活性肽以及疫苗、诊断试剂盒等领域。生物技术的进步使药物化学研究发生了很大的转变：过去占主导地位的是合成化学和天然产物的筛选，目前生物分子学已成为药物化学发展的推动力，而肽类药物的产品开发和生物分子学基础研究又有着天然的联系。通过体内、体外实验，结果发现：联合应用HER2及VEGF模拟肽对乳腺癌有着明显的抗肿瘤及抑制肿瘤血管生成的作用。日本科学家发现了HER2裂解混合肽，该肽对宫颈癌及乳腺癌细胞系均有较强的细胞毒性作用，甚至对曲妥珠单抗和拉帕替尼耐药的肿瘤细胞系亦有作用，而对正常的细胞系却无明显细胞毒效应；HER2裂解混合肽可以裂解过表达HER2的肿瘤细胞膜，对正常细胞的细胞膜却无裂解作用；通过静脉途经注射用药，混合肽可明显抑制无胸腺小鼠乳腺癌模型的肿瘤生长。上述研究成果也为治疗胃癌这一死亡率较高的恶性肿瘤开辟了新的途径。
发明内容
本发明的目的在于提供一种单链多肽，本发明还提供该多肽在制备用于预防和治疗胃癌的药物中的应用。
为实现上述目的，本发明可采取下述技术方案：
本发明所述的单链多肽由40个氨基酸组成；其氨基酸序列为SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQAR，简称WSGC肽，其分子量为4344g/mol。
本发明的单链多肽在制备用于预防和治疗胃癌的药物中的应用，其药物中的有效成分为WSGC肽。
本发明所述的特异性WSGC肽应用蛋白质组学技术可在胃癌患者血清中鉴定出，该肽在胃癌患者术前、术后及复发患者血清中呈动态性表达。鉴于该肽在在胃癌患者血清中的特异性表达，本发明首先通过FOMC-保护氨基酸固相合成法合成由40个氨基酸组成的WSGC肽，通过高效液相色谱(HPLC)对其进行纯化，使其纯度达到95%以上。
本发明的用于治疗胃癌的药物形式为单链化合物，可溶解于纯水、生理盐水或PBS缓冲液中。实验证明，本发明制备的多肽药物通过抑制胃癌细胞的增殖与生长，达到治疗胃癌的作用，并可在预防和治疗胃癌中得到广泛应用。
附图说明
图1为标记有FITC的WSGC肽与胃癌细胞共同培养48h后在两种显微镜下观察同一视野的结果。
图2为不同浓度梯度的WSGC肽干预胃癌细胞的生长曲线图。
图3为不同浓度梯度的WSGC肽对胃癌细胞生长的抑制率。
图4为未干预的胃癌细胞及WSGC肽在IC50、IC80浓度下干预胃癌细胞48h后流式细胞仪检测细胞凋亡图。
图5为未干预的胃癌细胞及WSGC肽在IC50、IC80浓度下干预胃癌细胞48h后流式细胞仪检测细胞周期图。
图6为典型的对照组和实验组持续腹腔注射生理盐水和WSGC肽6周后效果图。
图7为对照组和实验组持续腹腔注射生理盐水和WSGC肽6周后荷瘤鼠肿瘤体积对比。
具体实施方式
下面对本发明做更加详细的说明。其中所用的技术手段为本领域的常规手段，所用原料均为市售商品。
一、本发明单链多肽（WSGC肽）的氨基酸序列及物理特性见下表1。
表1
。
该单链多肽的制备方法如下：
1）采用Wang树脂作为载体，用二氯甲烷（DCM）将树脂充分溶胀后，用N-二甲基甲酰（DMF）清洗树脂几遍；
2）使用适当浓度的20%哌啶将9-芴甲氧羰基（Fomc）基团脱出，使用DMF清洗树脂数遍，洗去残余液；
3）称取适量的O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸（TBTU）及C端第二个Fomc-保护氨基酸进行偶联，偶联完毕后使用茚三酮检测法确保连接完全，再使用DMF清洗2遍，洗去残留的各种残基和缩合剂；
4）依WSGC肽氨基酸序列将各氨基酸逐个进行偶联，重复上述步骤3）；
5）将所有的氨基酸连接结束后，重复上述步骤2），脱去最后的FOMC-保护基团；
6）用切割液裂解树脂、氨基酸混合物，去除树脂和氨基酸保护基团，得到粗品；
7）质谱质谱仪检测WSGC肽粗品，确认产品正确；
8）采用高效液相色谱(HPLC)分离提纯粗品WSGC肽，至纯度>95%。
二、WSGC肽与胃癌细胞的融合
完整切除III/IV期胃癌志愿者的瘤体，在剖开的瘤体中选择生长良好的肿瘤标本，进行原代培养并鉴定为胃癌细胞系。使用荧光标记物FITC标记WSGC肽，将标记有FITC的WSGC肽与胃癌细胞共培养48h，在荧光显微镜下观察WSGC肽与细胞的融合情况，结果显示该多肽能够与胃癌细胞相结合，如图1所示，A.普通相差显微镜下观察，20×10倍镜；B.荧光显微镜下观察，20×10倍镜;C.A+B合并图。
三、WSGC肽干预胃癌细胞生长的体外试验
将经WSGC肽干预的胃癌细胞列为实验组，未经WSGC肽干预的胃癌细胞列为对照组：绘制细胞生长曲线，如图2所示。结果显示：WSGC肽对胃癌细胞的生长增殖起到抑制作用。经CCK8染色试剂处理后，酶标仪下获得相关数据，计算出细胞生长活性曲线（如图3所示）和WSGC肽24h、48h和72h半数抑制浓度(IC50)和80%抑制浓度(IC80)，结果如下表2所示。
表2 WSGC肽对胃癌细胞系生长抑制的24h、48h和72h半数抑制浓度（IC50）和80%抑制浓度(IC80)
流式细胞仪检测实验组与对照组的细胞凋亡率(如图4所示，A：WSGC肽浓度为0；B：WSGC肽浓度为IC50；C：WSGC肽浓度为IC80)和生长周期(如图5所示，A：WSGC肽浓度为0；B：WSGC肽浓度为IC50；C：WSGC肽浓度为IC80)，结果显示：未经干预的和经过浓度IC50、IC80的WSGC肽干预后的胃癌细胞在48小时的凋亡率分别为2.84%、42.05%和70.44%，WSGC肽可高效诱导胃癌细胞的凋亡；经过浓度IC50、IC80的WSGC肽干预后的胃癌细胞在S期的细胞比例高于未经干预的胃癌细胞，WSGC肽能够诱导S期阻滞，结果如下表3所示。
表3 IC50及IC80浓度的WSGC肽干预后的胃癌细胞不同细胞周期细胞比例(%,±s)
注：*** p<0.001，IC80、IC50与对照组之间比较均有统计学意义。
四、对本发明的WSGC肽设计动物实验，相关操作符合实验动物伦理规范。
对BALB/c无胸腺小鼠皮下种植胃癌细胞，成功构建荷瘤鼠。将腹腔注射生理盐水(4ml/kg)的荷瘤鼠列为对照组，腹腔注射WSGC肽(4mg/Kg)治疗的荷瘤鼠列为实验组。持续6周后结果显示：实验组小鼠的肿瘤体积较对照组明显缩小（图6中A为对照组，B为实验组；图7中p<0.0001，差异具有统计学意义）；实验组小鼠的体重和健康状况较对照组明显改善。以上结果表明WSGC肽能够有效地治疗胃癌，且副作用小。
Application Project
-------------------
<110> 王家祥 宋东建
<120> 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
<130> 2016
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 40
<212> PRT
<213> Homo sapiens
<400> 1
Ser Glu Ala Glu Asp Ala Ser Leu Leu Ser Phe Met Gln Gly
Tyr Met Lys His Ala Thr Lys Thr Ala Lys Asp Ala Leu Ser
Ser Val Gln Glu Ser Gln Val Ala Gln Gln Ala Arg
Claims (1)
1.一种单链多肽在制备用于治疗胃癌的药物中的应用，其特征在于：该单链多肽由40个氨基酸组成，其氨基酸序列为SEAEDASLLSFMQGYMKHATKTAKDALSSVQESQVAQQAR。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611138456.XA CN106519007B (zh) | 2016-12-12 | 2016-12-12 | 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611138456.XA CN106519007B (zh) | 2016-12-12 | 2016-12-12 | 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106519007A CN106519007A (zh) | 2017-03-22 |
| CN106519007B true CN106519007B (zh) | 2019-07-02 |
Family
ID=58343078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611138456.XA Expired - Fee Related CN106519007B (zh) | 2016-12-12 | 2016-12-12 | 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106519007B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418106A (zh) * | 2000-03-03 | 2003-05-14 | 史密丝克莱恩比彻姆生物有限公司 | 疫苗 |
| WO2005011724A1 (en) * | 2003-07-25 | 2005-02-10 | Cryptome Pharmaceuticals Ltd | A method of producing an anticoagulation effect |
| CN1946430A (zh) * | 2004-01-09 | 2007-04-11 | 财团法人牧岩生命工学研究所 | 包含人载脂蛋白(a)三环lk68或lk8基因作为有效成分用于治疗癌症的治疗剂,以及使用其治疗癌症的方法 |
| WO2009067546A3 (en) * | 2007-11-19 | 2009-12-17 | Celera Corpration | Lung cancer markers and uses thereof |
| CN102348979A (zh) * | 2009-03-09 | 2012-02-08 | 乔治亚大学研究基金公司 | 胃癌诊断用蛋白标记的鉴定 |
| CN103765212A (zh) * | 2011-06-27 | 2014-04-30 | 杰克逊实验室 | 治疗癌症和自体免疫性疾病的方法和组合物 |
| CN104204807A (zh) * | 2012-01-20 | 2014-12-10 | 阿德莱德研究及创新控股有限公司 | 用于胃癌的生物标志物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120177610A1 (en) * | 2007-09-19 | 2012-07-12 | Kieu Hoang | Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins |
-
2016
- 2016-12-12 CN CN201611138456.XA patent/CN106519007B/zh not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418106A (zh) * | 2000-03-03 | 2003-05-14 | 史密丝克莱恩比彻姆生物有限公司 | 疫苗 |
| WO2005011724A1 (en) * | 2003-07-25 | 2005-02-10 | Cryptome Pharmaceuticals Ltd | A method of producing an anticoagulation effect |
| CN1946430A (zh) * | 2004-01-09 | 2007-04-11 | 财团法人牧岩生命工学研究所 | 包含人载脂蛋白(a)三环lk68或lk8基因作为有效成分用于治疗癌症的治疗剂,以及使用其治疗癌症的方法 |
| WO2009067546A3 (en) * | 2007-11-19 | 2009-12-17 | Celera Corpration | Lung cancer markers and uses thereof |
| CN102348979A (zh) * | 2009-03-09 | 2012-02-08 | 乔治亚大学研究基金公司 | 胃癌诊断用蛋白标记的鉴定 |
| CN103765212A (zh) * | 2011-06-27 | 2014-04-30 | 杰克逊实验室 | 治疗癌症和自体免疫性疾病的方法和组合物 |
| CN104204807A (zh) * | 2012-01-20 | 2014-12-10 | 阿德莱德研究及创新控股有限公司 | 用于胃癌的生物标志物及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| Evolution of the apolipoproteins;Mark S. Boguski et al.;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;19861231;第6398-6407页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106519007A (zh) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104130315B (zh) | 一种特异靶向her2蛋白的多肽 | |
| EP2784093B1 (en) | Polyethylene glycol-modified integrin blocker hm-3 and use thereof | |
| JP6574175B2 (ja) | 細胞透過性ペプチド、及びそれを含むコンジュゲート | |
| CN104262460B (zh) | 一种靶向人乳腺癌细胞的多肽及其应用 | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| KR20090102772A (ko) | Ｈｌａ-ａ*1101 구속성 ｗｔ1 펩티드 및 이를 포함하는 의약 조성물 | |
| JP7376960B2 (ja) | 新規マイクロペプチドｈｍｍｗとその適用 | |
| EP3587440B1 (en) | Human pd-l1 high-protein-affinity peptide and use thereof | |
| CN104530199A (zh) | 一种抗肿瘤多肽及其制备方法和应用 | |
| JP2022544481A (ja) | ポリペプチドまたはその誘導体の応用 | |
| US10526370B2 (en) | Pentapeptide associated with integrin receptor alpha vbeta3 | |
| AU2012361902B2 (en) | Integrin blocker polypeptide and use thereof | |
| CN112409450B (zh) | TIGIT-IgV的亲和剂及其应用 | |
| CN106699850B (zh) | Rbbp4靶向多肽和抗肿瘤多肽及其应用 | |
| KR102666372B1 (ko) | 백혈병 세포 증식 억제 작용을 갖는 폴리펩티드 | |
| CN101838306A (zh) | 一种k4多肽合成产物及其应用 | |
| CN106519007B (zh) | 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用 | |
| KR20180086277A (ko) | 폴리펩티드 화합물, 그리고 이의 제조 방법 및 적용 | |
| CN105131089A (zh) | 一种十三肽及其应用 | |
| CN101838307A (zh) | 一种k2多肽合成产物及其应用 | |
| CN115838436A (zh) | 靶向ITGβ5-14-3-3ζ复合物的抗肿瘤多肽B5-X及其制备方法与用途 | |
| KR101323669B1 (ko) | 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드 | |
| CN110724179B (zh) | 一种抗肿瘤多肽及其制备方法和用途 | |
| CN116059348A (zh) | 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用 | |
| CN102190713A (zh) | 一种合成肽及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191212 Address after: 450052 the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, 27 District, Henan, Zhengzhou Co-patentee after: Wang Jiaxiang Patentee after: THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU University Address before: 450052 the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, 27 District, Henan, Zhengzhou Co-patentee before: Song Dongjian Patentee before: Wang Jiaxiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190702 |